TickerFacts.

Kura Oncology, Inc. (KURA): Revenue

Annual figures by period end, from SEC filings.

$67.48M
Year ended 2025-12-31
$77.22M
Trailing 12 months to 2026-06-30
2023-12-31: $02024-12-31: $53.88M2025-12-31: $67.48M$67.48M
2023-12-31 Revenue (USD) 2025-12-31
Period endedRevenueChange YoYSource filing
2025-12-31$67.48M+25.2%2026-03-05, From 2025-01-01
2024-12-31$53.88Mn/a2026-03-05, From 2024-01-01
2023-12-31$0n/a2026-03-05, From 2023-01-01

Revenue at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedRevenueChange YoY
Kura Oncology, Inc. (KURA)2025-12-31$67.48M+25.2%
Spero Therapeutics, Inc. (SPRO)2025-12-31$66.80M+39.2%
Rockwell Medical, Inc. (RMTI)2025-12-31$69.26M-31.8%
Enanta Pharmaceuticals Inc (ENTA)2025-09-30$65.32M-3.4%
Viridian Therapeutics, Inc. (VRDN)2025-12-31$70.85Mn/m
Fortress Biotech, Inc. (FBIO)2025-12-31$63.26M+9.7%
Assembly Biosciences, Inc. (ASMB)2025-12-31$72.30M+153.5%
Nuvation Bio Inc. (NUVB)2025-12-31$62.90M+699.0%
Bicycle Therapeutics PLC (BCYC)2025-12-31$72.59M+105.8%

Compare KURA, SPRO, RMTI, ENTA side by side · Screen every company in Pharmaceutical Preparations ↗